| P/E (FY) | — | Sales (TTM) | $16.8M |
| Earnings (TTM) | -$51.6M | ROE | — |
| Net Margin | −257.93% | ROIC | −289.80% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $96.5M | Trading Days | 259 |
| 52W High | 37.42 |
| 52W Low | 16.50 |
| % Off High | −25.79% |
| YTD | −10.42% | 1Y | 25.43% |
| Since incept. (ann.) | 62.63% |
Commercial Operations 96% · Research And Development Operations 4%
| Ann. Volatility (1Y) | 85.11% | Ann. Volatility (3Y) | 127.18% |
| Sharpe (1Y) | 0.69 | Sharpe (3Y) | 0.96 |
| Max Drawdown (1Y) | −51.39% | Max Drawdown (3Y) | −51.39% |
| Beta (3Y, vs SPY) | 2.20 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PROK | PROKIDNEY CORP. | $94.8M | — |
| TCRX | TScan Therapeutics, Inc. | $100.4M | — |
| BDTX | Black Diamond Therapeutics, Inc. | $100.9M | 4.5 |
| OTLK | Outlook Therapeutics, Inc. | $109.3M | — |
| CGTX | COGNITION THERAPEUTICS INC | $82.7M | — |
| VXRT | Vaxart, Inc. | $116.1M | 6.9 |
| KLRS | Kalaris Therapeutics, Inc. | $79.5M | — |
| ENGN | enGene Therapeutics Inc. | $117.9M | 0.8 |
| CRDL | Cardiol Therapeutics Inc. | $120.3M | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $76.8M | 16.8 |
| ATRA | Atara Biotherapeutics, Inc. | $70.4M | 3.0 |
| HUMA |
| Humacyte, Inc. |
| $140.0M |
| — |
